Chengdu Kanghua Biological Products Future Growth
Future criteria checks 2/6
Chengdu Kanghua Biological Products is forecast to grow earnings and revenue by 15.6% and 13.8% per annum respectively. EPS is expected to grow by 15.4% per annum. Return on equity is forecast to be 17% in 3 years.
Key information
15.6%
Earnings growth rate
15.4%
EPS growth rate
Biotechs earnings growth | 34.5% |
Revenue growth rate | 13.8% |
Future return on equity | 17.0% |
Analyst coverage | Low |
Last updated | 26 May 2024 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,379 | 884 | N/A | 886 | 5 |
12/31/2025 | 2,127 | 797 | N/A | 686 | 5 |
12/31/2024 | 1,868 | 709 | N/A | 809 | 5 |
3/31/2024 | 1,611 | 553 | 523 | 656 | N/A |
12/31/2023 | 1,577 | 509 | 417 | 574 | N/A |
9/30/2023 | 1,382 | 484 | 233 | 440 | N/A |
6/30/2023 | 1,421 | 531 | 72 | 384 | N/A |
3/31/2023 | 1,458 | 568 | -85 | 324 | N/A |
1/1/2023 | 1,447 | 598 | -224 | 195 | N/A |
9/30/2022 | 1,567 | 729 | -246 | 138 | N/A |
6/30/2022 | 1,400 | 893 | -310 | 83 | N/A |
3/31/2022 | 1,322 | 864 | -274 | 82 | N/A |
1/1/2022 | 1,292 | 829 | -185 | 130 | N/A |
9/30/2021 | 993 | 648 | -203 | 97 | N/A |
6/30/2021 | 1,136 | 478 | 35 | 213 | N/A |
3/31/2021 | 1,119 | 444 | 158 | 302 | N/A |
12/31/2020 | 1,039 | 408 | 234 | 370 | N/A |
9/30/2020 | 1,085 | 442 | 237 | 327 | N/A |
6/30/2020 | 739 | 285 | 188 | 263 | N/A |
3/31/2020 | 581 | 216 | 123 | 166 | N/A |
12/31/2019 | 555 | 187 | 159 | 183 | N/A |
9/30/2019 | 425 | 101 | 170 | 189 | N/A |
12/31/2018 | 559 | 154 | 23 | 57 | N/A |
12/31/2017 | 262 | 74 | N/A | 90 | N/A |
12/31/2016 | 93 | 7 | N/A | 3 | N/A |
12/31/2015 | 71 | 12 | N/A | 7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300841's forecast earnings growth (15.6% per year) is above the savings rate (2.9%).
Earnings vs Market: 300841's earnings (15.6% per year) are forecast to grow slower than the CN market (22% per year).
High Growth Earnings: 300841's earnings are forecast to grow, but not significantly.
Revenue vs Market: 300841's revenue (13.8% per year) is forecast to grow faster than the CN market (13.5% per year).
High Growth Revenue: 300841's revenue (13.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300841's Return on Equity is forecast to be low in 3 years time (17%).